ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL

被引：0
|
作者：
Ji-Yu Li
Yu-Yang Li
Wei Jin
Qing Yang
Zhi-Ming Shao
Xing-Song Tian
机构：
[1] Provincial Hospital Affiliated to Shandong University,Department of Breast and Thyroid Surgery
[2] The Second Hospital of Shandong University,Department of Breast Surgery
[3] Breast Cancer Institute,Department of Breast Surgery
[4] Shanghai Cancer Center,undefined
[5] Shanghai Medical College,undefined
[6] Fudan University,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 31卷
关键词：
ABT-737; Breast cancer; Acquired radioresistance; Radiation; Bcl-2; Bcl-xL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
    Li, Ji-Yu
    Li, Yu-Yang
    Jin, Wei
    Yang, Qing
    Shao, Zhi-Ming
    Tian, Xing-Song
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
  • [2] The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells
    Allaman-Pillet, Nathalie
    Oberson, Anne
    Munier, Francis
    Schorderet, Daniel F.
    OPHTHALMIC GENETICS, 2013, 34 (1-2) : 1 - 13
  • [3] The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin
    Witham, James
    Valenti, Melanie R.
    De-Haven-Brandon, Alexis K.
    Vidot, Susanne
    Eccles, Suzanne A.
    Kaye, Stan B.
    Richardson, Alan
    CLINICAL CANCER RESEARCH, 2007, 13 (23) : 7191 - 7198
  • [4] Radiochemosensitization of primary glioma stem cells by the Bcl-2/Bcl-xL inhibitor ABT-737
    Dheenadayalan, R.
    Firat, E.
    Niedermann, G.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 118 - 118
  • [5] ABT-737, an inhibitor of Bcl-2/Bcl-XL proteins, is cytotoxic in multiple myeloma cells.
    Kline, M
    Kimlinger, T
    Timm, M
    Haug, J
    Lust, JA
    Rajkumar, SV
    Kumar, S
    BLOOD, 2005, 106 (11) : 455A - 455A
  • [6] 'Aerobically poised' leukaemia cells are resistant to the mitochondrial toxin and BCL-2/BCL-XL inhibitor, ABT-737
    Miles, Gareth
    Langlais, Claudia
    MacFarlane, Marion
    Cain, Kelvin
    TOXICOLOGY LETTERS, 2014, 229 : S74 - S74
  • [7] A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
    Chauhan, D.
    Velankar, M.
    Brahmandam, M.
    Hideshima, T.
    Podar, K.
    Richardson, P.
    Schlossman, R.
    Ghobrial, I.
    Raje, N.
    Munshi, N.
    Anderson, K. C.
    ONCOGENE, 2007, 26 (16) : 2374 - 2380
  • [8] A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
    D Chauhan
    M Velankar
    M Brahmandam
    T Hideshima
    K Podar
    P Richardson
    R Schlossman
    I Ghobrial
    N Raje
    N Munshi
    K C Anderson
    Oncogene, 2007, 26 : 2374 - 2380
  • [9] Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
    Merino, Delphine
    Khaw, Seong L.
    Glaser, Stefan P.
    Anderson, Daniel J.
    Belmont, Lisa D.
    Wong, Chihunt
    Yue, Peng
    Robati, Mikara
    Phipson, Belinda
    Fairlie, Walter D.
    Lee, Erinna F.
    Campbell, Kirsteen J.
    Vandenberg, Cassandra J.
    Cory, Suzanne
    Roberts, Andrew W.
    Ludlam, Mary J. C.
    Huang, David C. S.
    Bouillet, Philippe
    BLOOD, 2012, 119 (24) : 5807 - 5816
  • [10] Crystal structure of ABT-737 complexed with Bcl-xL:: implications for selectivity of antagonists of the Bcl-2 family
    Lee, E. F.
    Czabotar, P. E.
    Smith, B. J.
    Deshayes, K.
    Zobel, K.
    Colman, P. M.
    Fairlie, W. D.
    CELL DEATH AND DIFFERENTIATION, 2007, 14 (09): : 1711 - 1713
12345